Behavioral Health

Serotonin syndrome: recognition and management

Clinical Overview and When to Suspect Serotonin Syndrome

— SSRI/SNRI + MAOI (including linezolid, methylene blue, phenelzine, selegiline) — classic exam stem

— SSRI + tramadol, meperidine, fentanyl, dextromethorphan, ondansetron, metoclopramide, triptans

— MDMA, cocaine, LSD, St. John's wort, ginseng

— Overdose of a single serotonergic agent

— Switching antidepressants without adequate washout (fluoxetine requires 5-week washout before MAOI due to long half-life of norfluoxetine)

— Spontaneous clonus

— Inducible clonus + agitation or diaphoresis

— Ocular clonus + agitation or diaphoresis

— Tremor + hyperreflexia

— Hypertonia + temp >38°C + ocular or inducible clonus

Board pearl: A patient on fluoxetine started on linezolid for MRSA who develops tremor, diaphoresis, and clonus 8 hours later — that's the prototype Step 3 vignette. The ED move is stop all serotonergic agents immediately, supportive care, benzodiazepines, and consider cyproheptadine for moderate-severe cases. Mortality is low when recognized early but rises sharply with hyperthermia >41.1°C.

Definition: Life-threatening hyperserotonergic state from excess CNS and peripheral 5-HT activity, most often iatrogenic from drug combinations or overdose, not idiosyncratic.

Core triad (Sternbach): mental status changes + autonomic hyperactivity + neuromuscular abnormalities (especially clonus, hyperreflexia, rigidity — lower extremity predominant).

Time course: Onset typically <24 hours after a new serotonergic agent, dose increase, or drug interaction; ~60% within 6 hours. Distinguishes it from NMS (days to weeks).

When to suspect — the high-yield triggers:

Hunter Criteria (more sensitive/specific than Sternbach): serotonergic agent + one of:

Presentation Patterns and Key History

— Mild: afebrile, tachycardia, mydriasis, diaphoresis, intermittent tremor, hyperreflexia — often missed or attributed to anxiety

— Moderate: temp 38–40°C, hypertension, hyperactive bowel sounds/diarrhea, inducible or ocular clonus, agitation, pressured speech

— Severe: temp >41°C, severe rigidity (truncal > limb), sustained clonus, delirium, autonomic instability, rhabdomyolysis, DIC, seizures

— Full medication reconciliation including OTC (dextromethorphan cough syrup), herbals (St. John's wort, SAMe), and recreational drugs (MDMA, cocaine)

— Recent dose changes, new prescriptions, antibiotic starts (linezolid), or use of methylene blue intraoperatively

— Pain management — tramadol, meperidine, fentanyl

— Anti-emetics — ondansetron, metoclopramide

— Migraine treatment — triptans, ergots

— Recent psychiatric medication switch and washout interval

— Suicidal ideation suggesting intentional overdose

— GI hyperactivity (diarrhea, hyperactive bowel sounds) — uncommon in NMS or anticholinergic toxidrome

— Lower-extremity clonus more than upper

— Rapid onset over hours, not days

— Mydriasis with diaphoresis (vs anticholinergic: dry skin)

Key distinction: Serotonin syndrome features hyperkinesis (tremor, clonus, hyperreflexia, restless gut), while NMS features hypokinesis (lead-pipe rigidity, bradyreflexia, akinesis). The same patient on both an SSRI and an antipsychotic can confuse the picture — anchor on the time course (hours vs days) and the clonus finding.

Step 3 management: Always perform an independent medication reconciliation on arrival; don't trust the EMR list alone — confirm OTC and herbal use directly with the patient or family.

Spectrum of severity:

Key history questions on the Step 3 stem:

Symptom hallmarks pointing to serotonin syndrome over other toxidromes:

Physical Exam Findings and Hemodynamic Assessment

— Tachycardia (often >120)

— Hypertension early; hypotension in severe disease from autonomic collapse

— Hyperthermia — driven by sustained muscle activity, not central thermoregulation; correlates with severity and mortality risk

— Tachypnea

— Clonus: spontaneous, inducible (dorsiflex foot abruptly), or ocular (slow continuous horizontal eye movements) — most specific finding

— Hyperreflexia, lower > upper extremity

— Tremor, myoclonus, shivering

— Rigidity — generalized in severe cases, can mimic NMS

— Mental status: anxiety, agitation, confusion, delirium → coma

— Mydriasis (dilated pupils, reactive)

— Diaphoresis with moist skin (vs anticholinergic dry skin)

— Flushing

— Hyperactive bowel sounds, diarrhea

— Sialorrhea

— Continuous cardiac monitoring — QT prolongation possible with citalopram/escitalopram overdose

— Core temperature monitoring (rectal or bladder probe); axillary readings underestimate

— End-tidal CO2 if intubated; metabolic acidosis common

— Volume status — patients are often dry from diaphoresis and decreased intake

CCS pearl: Order "continuous cardiac telemetry, continuous pulse oximetry, rectal temperature probe, large-bore IV access ×2, normal saline 1 L bolus, finger-stick glucose" as your initial monitoring/resuscitation package. Recheck vitals q15 min in moderate disease.

Board pearl: Ocular clonus + agitation + diaphoresis in a patient on an SSRI satisfies Hunter criteria — you don't need a lab test to make the diagnosis. Imaging and CSF are normal in pure serotonin syndrome and should not delay treatment.

Vital signs:

Neurologic exam — the diagnostic anchor:

Autonomic exam:

Hemodynamic assessment priorities:

Diagnostic Workup — Initial Labs, Imaging, ECG

— CBC — leukocytosis common, nonspecific

— BMP — hyperkalemia from rhabdo, AKI, anion gap acidosis

— CK — elevation marks rhabdomyolysis; trend q6h if elevated

— LFTs — transaminitis in severe disease

— Coags (PT/INR, PTT, fibrinogen, platelets, d-dimer) — screen for DIC in hyperthermic patients

— Lactate, ABG/VBG — metabolic/lactic acidosis from sustained muscle activity

— UA + urine myoglobin — pigmenturia from rhabdomyolysis

— Urine pregnancy in reproductive-age women

— Acetaminophen and salicylate levels if intentional overdose suspected

— Urine drug screen — looking for cocaine, amphetamines, MDMA

— TSH — thyroid storm is on the differential

— Sinus tachycardia typically

— QTc prolongation — citalopram, escitalopram, methadone, ondansetron coingestions

— Rule out ischemia in older patients with chest pain

— CT head (non-contrast) if altered mental status without clear cause, focal deficits, or trauma — typically normal

— CXR if hypoxia, aspiration concern, or planning intubation

— Serum serotonin levels — not clinically useful, slow turnaround

— LP unless meningoencephalitis is competing on the differential

Step 3 management: Pair labs with the order set for aggressive cooling (cool IV fluids, evaporative cooling, ice packs to groin/axillae) when temp >38.5°C. Antipyretics like acetaminophen are ineffective because hyperthermia is muscular, not hypothalamic.

Board pearl: A normal CK does not exclude serotonin syndrome — it just means you caught it early.

Serotonin syndrome is a clinical diagnosis (Hunter criteria); labs are for severity assessment, complication screening, and excluding mimics.

Essential initial labs:

ECG:

Imaging:

What you do NOT need:

Diagnostic Workup — Advanced or Confirmatory Studies

— Spontaneous clonus

— Inducible clonus + agitation or diaphoresis

— Ocular clonus + agitation or diaphoresis

— Tremor + hyperreflexia

— Hypertonia + temp >38°C + ocular or inducible clonus

— EEG if status epilepticus suspected or non-convulsive seizure considered in altered patient

— MRI brain if focal findings, suspected encephalitis, or stroke mimic

— CSF analysis (cell count, glucose, protein, HSV PCR) — only if meningoencephalitis cannot be excluded; will be normal in serotonin syndrome

— TSH, free T4 to rule out thyroid storm

— Cortisol if adrenal crisis on the differential

— Antipsychotic levels (e.g., clozapine) — typically not actionable acutely

— Indicated for severe presentations, polypharmacy overdose, pediatric exposures, or pregnancy

— Document the consult in the chart — this is both quality-of-care and medico-legal practice

— Psychiatry for medication reconciliation, intentional overdose, suicide risk assessment

— Neurology if diagnosis remains uncertain or status epilepticus

— Critical care for ICU triage

Key distinction: Hunter criteria require clonus or tremor + hyperreflexia as the neuromuscular anchor. Without one of these, reconsider the diagnosis — particularly NMS (rigidity without clonus), anticholinergic toxidrome (dry skin, hypoactive bowel sounds), or malignant hyperthermia (post-anesthesia, masseter rigidity).

CCS pearl: "Consult Toxicology" and "Consult Psychiatry" early on the CCS interface — both contribute to optimal management scoring when intentional ingestion is suspected.

There is no confirmatory test — diagnosis remains clinical via Hunter Serotonin Toxicity Criteria (84% sensitive, 97% specific vs Sternbach's older criteria).

Hunter criteria refresher (must have serotonergic agent + one):

Adjunctive studies when diagnosis is unclear:

Toxicology consult / Poison Control (1-800-222-1222):

Specialty consults:

Risk Stratification and First-Line Management Logic

— Mild (afebrile, hyperreflexia, tremor): discontinue offending agent, supportive care, observation 6–24 hours, often discharge home

— Moderate (temp 38–40°C, agitation, sustained clonus): ED/observation, IV benzodiazepines, IV fluids, consider cyproheptadine, telemetry admission

— Severe (temp >41°C, rigidity, autonomic instability, AMS): ICU admission, intubation with non-depolarizing paralysis (vecuronium/rocuronium), aggressive cooling, hemodynamic support

— 1. Discontinue all serotonergic agents — single most important step

— 2. Supportive care — IV fluids, O2, cardiac monitoring

— 3. Control agitation and muscle activity — benzodiazepines (lorazepam 1–2 mg IV or diazepam 5–10 mg IV, titrate)

— 4. Active cooling if temp >38.5°C — evaporative cooling, cold IV fluids, ice packs; paralyze if temp >41°C

— 5. Serotonin antagonist — cyproheptadine for moderate-severe cases

— Physical restraints alone — worsen isometric muscle contraction → hyperthermia, rhabdo, lactic acidosis

— Succinylcholine — hyperkalemia risk in rhabdomyolysis

— Antipyretics — ineffective (peripheral muscle source)

— Bromocriptine, dantrolene — these are for NMS/malignant hyperthermia, not serotonin syndrome

— Propranolol — long-acting, can mask hemodynamic deterioration

Step 3 management: Benzodiazepines are first-line for both agitation and autonomic instability — they reduce muscle activity, lower heart rate and BP, and decrease metabolic heat production. Titrate aggressively; do not under-dose out of fear of sedation.

Board pearl: Hyperthermia >41.1°C is a medical emergency — immediate sedation, intubation, paralysis, and ice-water cooling are mandatory.

Severity-based management framework:

The five pillars of treatment (in order):

What to AVOID:

Pharmacotherapy — First-Line Drug Regimen

— Lorazepam 1–2 mg IV q10–15 min, titrate to calm, non-agitated state

— Diazepam 5–10 mg IV q10 min — preferred by some for rapid onset

— Midazolam 2–5 mg IV for rapid effect, shorter duration

— Endpoints: HR <120, BP normalized, decreased rigidity, reduced clonus

— Reduce metabolic demand → temperature reduction

— Oral or NG only (no IV form available in US)

— Loading: 12 mg PO/NG ×1

— Maintenance: 2 mg q2h if symptoms persist

— Maximum: 32 mg/day

— Once stable: 8 mg q6h until resolution

— Side effects: sedation, anticholinergic effects, hypotension

— Evidence is anecdotal but biologically plausible; reasonable when benzos and supportive care insufficient

— Chlorpromazine 50–100 mg IM — historical use; risks hypotension, lowers seizure threshold, can complicate NMS differential — generally avoided in modern practice

— Olanzapine 10 mg SL — anecdotal

— Short-acting agents only: esmolol, nitroprusside, nicardipine

— Avoid long-acting beta-blockers (propranolol) — risk of unopposed alpha and protracted hypotension

— IV fluids first

— Direct sympathomimetics (norepinephrine, epinephrine, phenylephrine) preferred

— Avoid dopamine — requires conversion to NE, unpredictable in adrenergic dysregulation

Board pearl: Cyproheptadine 12 mg loading dose PO/NG is the most testable specific therapy on Step 3.

Benzodiazepines — cornerstone:

Cyproheptadine (5-HT2A antagonist) — second-line, moderate-severe:

Alternative serotonin antagonists:

Hypertension management:

Hypotension management:

Antiemetics — DO NOT use ondansetron or metoclopramide (both serotonergic). Use droperidol cautiously or just benzodiazepines.

Expanded Pharmacology — Cooling, Airway, and Refractory Care

— Remove clothing, expose patient

— Evaporative cooling: tepid water mist + fans

— Ice packs to groin, axillae, neck

— Cold IV crystalloid (0.9% NaCl at 4°C)

— Cooling blankets

— Goal: temp <38.5°C, then discontinue active cooling to avoid overshoot hypothermia

— Rapid sequence intubation with etomidate or ketamine

— Non-depolarizing neuromuscular blockade — vecuronium or rocuronium (NOT succinylcholine — hyperkalemia in rhabdo)

— Paralysis eliminates muscle-generated heat — fastest cooling intervention

— Continuous sedation (propofol or midazolam infusion)

— Mechanical ventilation with normocapnia target

— IV NS or LR to maintain urine output 1–2 mL/kg/hr

— Monitor CK q6h; trend downward expected

— Avoid bicarbonate routinely; reserve for severe acidosis (pH <7.1) or hyperkalemia with ECG changes

— Replace electrolytes — potassium, magnesium, phosphate

— First-line: benzodiazepines (already on board)

— Second-line: levetiracetam, valproate

— Avoid phenytoin in toxin-induced seizures (limited efficacy)

— Supportive — FFP, cryoprecipitate, platelets as indicated by labs and bleeding

— Treat underlying hyperthermia and muscle injury

— Consider extracorporeal cooling

— Renal replacement therapy for AKI from rhabdomyolysis

— Continuous EEG if persistent altered mental status

CCS pearl: On the CCS, order in this sequence: stop offending drug → IV access → lorazepam → labs/ECG → active cooling → cyproheptadine → ICU transfer. Advancing the clock 30 minutes at a time lets you reassess vitals and titrate sedation appropriately.

Active cooling protocol for temp >38.5°C:

Severe hyperthermia (>41.1°C) — emergency:

Volume resuscitation and rhabdo prevention:

Seizure management:

DIC management:

Refractory cases:

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher risk due to polypharmacy — antidepressants + tramadol + ondansetron is a common combo in this population

— Reduced hepatic clearance prolongs half-life of SSRIs (especially fluoxetine, paroxetine)

— Atypical presentations — confusion may dominate over autonomic findings

— Lower threshold for ICU admission

— Start benzodiazepines at half the usual dose (lorazepam 0.5 mg IV); titrate carefully — delirium risk

— Beware concurrent frailty and falls risk

— Reduced metabolism of most SSRIs (CYP2D6, CYP3A4 substrates)

— Lorazepam preferred over diazepam — lorazepam undergoes glucuronidation, less affected by hepatic dysfunction

— Avoid acetaminophen even though it's not therapeutic for this fever

— Monitor INR if cirrhotic — DIC risk amplified

— Many SSRIs renally cleared metabolites (e.g., venlafaxine) — prolonged duration after discontinuation

— Adjust benzodiazepine choice — lorazepam, oxazepam, temazepam ("LOT") are preferred (no active renal metabolites)

— Monitor for rhabdomyolysis-induced AKI — aggressive IV fluids, early nephrology consult if Cr rising

— Consider CRRT for severe AKI with hyperkalemia or volume overload

— Avoid NSAIDs in recovery phase

— SSRI + tramadol (very common)

— SSRI + linezolid (UTI, MRSA treatment)

— SSRI + ondansetron (chemo, post-op nausea)

— Triptan + SSRI (migraine + depression)

— Methylene blue intraoperatively in patients on SSRIs — anesthesia red flag

Step 3 management: When discharging an elderly patient on multiple psychotropics, perform medication reconciliation with the outpatient pharmacist and deprescribe when feasible. Document indication for each serotonergic drug.

Board pearl: Fluoxetine has a 5-week washout requirement before starting an MAOI — longest of all SSRIs.

Elderly patients (>65):

Hepatic impairment:

Renal impairment:

Drug-drug interaction red flags in elderly:

Special Populations — Pregnancy, Pediatrics, and Postoperative

— SSRI use during pregnancy is common; continue if benefits outweigh risks

— Serotonin syndrome can occur in mother from same triggers

— Neonatal adaptation syndrome in third-trimester SSRI exposure — transient tremor, jitteriness, feeding issues, not true serotonin syndrome

— Treatment in pregnancy: same first-line approach — discontinue offending agent, benzodiazepines (lorazepam category D but benefits outweigh in life-threatening illness), cyproheptadine (category B)

— Avoid teratogen exposure during workup — limit CT if MRI feasible

— Continuous fetal monitoring if viable gestation (>23 weeks)

— OB consult mandatory

— Increasing pediatric SSRI prescriptions → rising incidence

— Common pediatric triggers: dextromethorphan OTC cough medicine, SSRI overdose in adolescents, accidental ingestion

— Symptoms similar but clonus may be subtle in young children

— Dose benzodiazepines by weight (lorazepam 0.05–0.1 mg/kg IV)

— Cyproheptadine pediatric dose: 0.25 mg/kg/day divided q6h (max 12 mg/day in young children)

— Consider non-accidental ingestion in toddlers — social work involvement

— Adolescents — screen for suicidal intent

— Methylene blue for vasoplegia, parathyroidectomy, methemoglobinemia — potent MAOI

— Fentanyl is weakly serotonergic — high doses + SSRI = risk

— Linezolid for surgical infections

— Meperidine for post-op shivering — avoid in SSRI patients

— Ondansetron for PONV — avoid in moderate doses if patient on SSRI/SNRI

— Pre-op medication reconciliation is essential; document SSRI status on anesthesia record

Key distinction: Neonatal SSRI withdrawal/adaptation is self-limited and managed with supportive care; do not give cyproheptadine reflexively to neonates.

Pregnancy:

Pediatrics:

Postoperative / perioperative:

Complications and Adverse Outcomes

— Rhabdomyolysis — CK often >5,000–50,000; presents with myoglobinuria, AKI, hyperkalemia, hyperphosphatemia, hypocalcemia

— Acute kidney injury — pigment nephropathy from myoglobin; goal urine output 1–2 mL/kg/hr

— Disseminated intravascular coagulation — endothelial injury from hyperthermia; bleeding, microthrombi

— Multi-organ failure — liver, kidney, CNS injury

— Metabolic acidosis — lactic from muscle activity and tissue hypoperfusion

— Tachyarrhythmias (sinus tach, SVT, AF)

— QT prolongation → torsades (citalopram, escitalopram, methadone overdose)

— Hypertensive urgency/emergency

— Hypotension and shock in severe disease

— Myocardial ischemia from supply-demand mismatch in patients with CAD

— Status epilepticus

— Permanent neurologic injury if hyperthermia prolonged

— Cerebral edema in severe cases

— Encephalopathy persisting after acute resolution

— Aspiration pneumonitis from altered mental status

— ARDS in severe systemic illness

— Respiratory failure requiring mechanical ventilation

Board pearl: A patient with serotonin syndrome and temp >41.1°C has crossed into "hyperthermic emergency" — order STAT intubation, paralysis with vecuronium, and aggressive ice-water cooling. Every minute counts.

Step 3 management: Trend CK q6h, creatinine q12h, coags q12h for the first 24–48 hours in moderate-severe cases. Discharge only after labs trend down and clinical resolution sustained ≥24 hours.

Hyperthermia-driven complications (the major killers):

Cardiovascular:

Neurologic:

Pulmonary:

Compartment syndrome — sustained muscle contraction; check pressures in tight, swollen extremities

Death — mortality ~2–12% overall, much higher with temp >41.1°C; usually from MOF, DIC, or arrhythmia

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Temp ≥40°C or rising despite cooling

— Need for intubation/mechanical ventilation

— Need for neuromuscular blockade

— Hemodynamic instability requiring vasopressors

— Severe rhabdomyolysis (CK >10,000 or AKI)

— Status epilepticus

— DIC

— Altered mental status with airway concerns

— Severe agitation refractory to bolus benzodiazepines

— Moderate severity — sustained clonus, temp 38–40°C, requires IV benzos and observation

— Cyproheptadine initiated

— CK 1,000–10,000 trending down

— Hemodynamically stable but requires q1–2h vitals

— Mild cases with resolving symptoms after offending agent stopped

— Tolerating PO, stable vitals, normal labs

— Reliable follow-up

— Truly mild cases, symptoms fully resolved, normal vitals × 6 hours, normal CK

— Reliable caregiver, clear written instructions to avoid serotonergic agents

— Outpatient psychiatry/PCP follow-up within 48–72 hours

— No active suicidality

— Toxicology / Poison Control — moderate-severe cases

— Psychiatry — intentional overdose, ongoing depression management, medication restart planning

— Critical care — for ICU triage

— OB — pregnant patients

— Pharmacy — medication reconciliation for polypharmacy patients

CCS pearl: On the CCS interface, "Transfer patient to ICU" is a discrete order; sequence it immediately after stabilizing the airway and starting cooling. Do not advance the clock more than 30 minutes without reassessing vitals in a moderate/severe case.

Board pearl: Even patients who appear to recover quickly need at least 24 hours of observation because long-half-life serotonergic drugs (fluoxetine, MAOIs) can produce delayed deterioration.

ICU admission criteria:

Step-down/telemetry admission:

Floor/observation:

Discharge from ED:

Mandatory consults:

Key Differentials — Same-Category Toxidromes/Hyperthermia Syndromes

— Trigger: dopamine antagonist (antipsychotic) — haloperidol, risperidone, olanzapine; or dopamine agonist withdrawal (PD meds stopped abruptly)

— Onset: days to weeks, slower

— Findings: lead-pipe rigidity, bradyreflexia, hypokinesis, hyperthermia, autonomic instability, severely elevated CK

— Treatment: dantrolene, bromocriptine, supportive care

— No clonus, no hyperreflexia, no GI hyperactivity

— Trigger: volatile anesthetics (halothane, sevoflurane) or succinylcholine

— Onset: minutes after exposure during/after anesthesia

— Findings: masseter rigidity, hyperthermia, hypercarbia (rising ETCO2), metabolic acidosis

— Treatment: dantrolene, stop trigger agent, supportive care

— Genetic — RYR1 mutation; family history clue

— Trigger: TCAs, antihistamines (diphenhydramine), atropine, scopolamine, jimsonweed

— Findings: "hot as a hare, dry as a bone, red as a beet, mad as a hatter, blind as a bat" — dry skin (vs diaphoretic in SS), hypoactive bowel sounds (vs hyperactive), urinary retention, mydriasis

— Treatment: physostigmine (in pure anticholinergic toxicity), benzodiazepines

— Trigger: cocaine, methamphetamine, MDMA, bath salts

— Findings: similar autonomic hyperactivity, diaphoresis, mydriasis — but no clonus or hyperreflexia typically

— MDMA can cause both — overlap exists

— Treatment: benzodiazepines

Key distinction: NMS = hypokinetic, slow-onset, dopamine blockade; Serotonin syndrome = hyperkinetic, fast-onset, serotonin excess. The same patient can be on both an antipsychotic and an SSRI — anchor on clonus (SS) vs lead-pipe rigidity (NMS) and time course.

Board pearl: Dantrolene is for MH and NMS; cyproheptadine is for serotonin syndrome. Do not mix them up.

Neuroleptic Malignant Syndrome (NMS):

Malignant Hyperthermia:

Anticholinergic toxidrome:

Sympathomimetic toxidrome:

Key Differentials — Other-Category Mimics

— Hyperthermia, tachycardia, AMS, tremor, agitation

— History of hyperthyroidism, recent infection, surgery, iodine exposure

— Labs: suppressed TSH, elevated free T4/T3

— Treatment: PTU/methimazole, beta-blockers, iodine, steroids

— No clonus typically; check thyroid function in unclear presentations

— Fever, tachycardia, AMS, hypotension

— Source identifiable — pulmonary, urinary, abdominal

— Lactate, procalcitonin elevated

— Treatment: antibiotics, fluids, source control

— Fever, AMS, headache, neck stiffness, focal deficits

— LP findings diagnostic (pleocytosis, low glucose, +PCR)

— Treatment: empiric vancomycin + ceftriaxone + acyclovir + dexamethasone

— Environmental exposure or exertional

— Anhidrosis (classic) or diaphoresis (exertional)

— No serotonergic drug history; no clonus

— Treatment: aggressive cooling

— Tremor, tachycardia, diaphoresis, agitation, hyperthermia, seizures

— Discontinuation of chronic alcohol or benzo use 48–96 hours prior

— Treatment: benzodiazepines (same as SS, conveniently)

— No clonus typically

— Episodic hypertension, headache, diaphoresis, palpitations

— Plasma/urine metanephrines elevated

— Treatment: phentolamine, then beta-blockade

— Rigidity, spasms — rare but considered in atypical presentations

Step 3 management: When the differential includes meningitis and serotonin syndrome, do not delay empiric antibiotics while pursuing LP — give ceftriaxone, vancomycin, acyclovir, dexamethasone empirically, then narrow once diagnosis clarified.

Board pearl: A patient on an SSRI plus an antipsychotic with hyperthermia and rigidity is a classic ambiguous stem — look for clonus (favor SS), time course (hours = SS), and dopamine blocker recently started (favor NMS).

Thyroid storm:

Sepsis with delirium:

Meningoencephalitis:

Heat stroke:

Alcohol/sedative withdrawal (DTs):

Pheochromocytoma crisis:

Strychnine poisoning, tetanus:

Secondary Prevention, Discharge Medications, and Long-Term Plan

— In general, wait until full symptom resolution (typically 24–72 hours) and patient is medically stable

— Restart only one agent at a time, at lower dose

— Avoid the combination that triggered the episode permanently — document in chart and discharge summary

— If MAOI was involved, 5-week washout from fluoxetine, 2 weeks from other SSRIs before restart of MAOI; 2 weeks after MAOI before SSRI restart

— Single SSRI or SNRI at therapeutic dose typically continues if depression treatment indicated

— Avoid: tramadol, meperidine, dextromethorphan-containing cough/cold preparations, St. John's wort, MDMA, triptans (relative contraindication if on SSRI — use cautiously)

— Antiemetics: prochlorperazine or droperidol preferred over ondansetron in patients on serotonergic agents

— Pain: acetaminophen, NSAIDs (if renal function permits), morphine, hydromorphone — avoid tramadol, meperidine, fentanyl high doses

— Written list of medications to avoid — give the actual drug names

— Warn about OTC cough syrup (dextromethorphan), herbal supplements (St. John's wort, SAMe, ginseng)

— Advise informing all providers (dentist, surgeon, ED) about the episode

— MedicAlert bracelet consideration

— Required if intentional overdose; psychiatric admission may be needed

— Safety plan, lethal means restriction (limit pill supply to PCP)

— Outpatient psychiatry referral with appointment scheduled before discharge

Step 3 management: The discharge medication reconciliation must include review with the patient and family, fax to the PCP, and call to the outpatient pharmacy in complex cases. This is a value-based-care and patient-safety priority.

Board pearl: Linezolid + SSRI is the most common avoidable iatrogenic trigger — document the SSRI allergy/interaction in the EMR as a hard stop.

Restarting serotonergic medications:

Discharge medication list — what's safe:

Patient education at discharge:

Suicidality screening:

Follow-Up, Monitoring Parameters, and Counseling

— PCP visit within 48–72 hours of discharge for medication review

— Psychiatry follow-up within 1–2 weeks if antidepressant restart or modification needed; sooner if intentional overdose

— Toxicology clinic referral if available, particularly for recurrent or refractory cases

— Repeat BMP, CK at 48–72 hours if renal injury or rhabdomyolysis occurred

— Symptom resolution: tremor, hyperreflexia, clonus should resolve over 24–72 hours

— Mental status — should return to baseline; persistent AMS warrants neurology consult and brain imaging

— Vital signs — recheck at 48 hours

— Hydration and PO intake

— Adherence to revised medication regimen

— Pharmacogenomic testing — consider in patients with recurrent serotonin syndrome or unusual sensitivity; CYP2D6 poor metabolizers at higher risk with certain SSRIs (paroxetine, fluoxetine)

— Depression treatment optimization — may need to switch antidepressant class entirely (e.g., to bupropion, which is non-serotonergic)

— Pain management plan — coordinate with PCP to avoid future tramadol prescriptions

— Educate on early warning signs — tremor, restlessness, sweating after medication changes

— Importance of disclosing all OTC and herbal use to clinicians

— Pharmacist counseling at every new prescription

— When to call 911 vs PCP

— Severe cases with prolonged ICU stay may need PT/OT for deconditioning

— Neuropsychiatric testing if persistent cognitive deficits

— Cardiac rehab not typically indicated unless complicated by MI or arrhythmia

CCS pearl: Order "Patient education: serotonergic drug avoidance" and "Follow-up appointment: PCP in 48 hours, Psychiatry in 1 week" as discrete items on the CCS discharge plan to earn management points.

Follow-up timing:

Monitoring parameters during recovery:

Long-term considerations:

Counseling points:

Rehabilitation:

Ethical, Legal, and Patient Safety Considerations

— Serotonin syndrome is often prescriber-induced (e.g., adding linezolid to a patient on sertraline without recognizing the interaction)

— Ethical duty to disclose the medical error to the patient and family — transparency improves trust, reduces litigation

— Document the event, the recognition, and the corrective action taken

— Report to hospital patient safety / quality improvement committee for root-cause analysis

— Suspected non-accidental ingestion in pediatrics → Child Protective Services

— Adult intentional overdose → psychiatric hold (e.g., 5150 in CA, similar statutes elsewhere) if active suicide risk

— Impaired driving if discharged on sedating regimen — counsel patient

— Adverse drug event reporting to FDA MedWatch if novel or severe

— Patients presenting with severe SS lack capacity due to AMS

— Emergency exception to informed consent applies — proceed with life-saving treatment (intubation, paralysis, cooling)

— Engage surrogate decision-makers (spouse, parent, healthcare proxy) when possible

— Document capacity assessment when stable enough to participate

— Medication reconciliation at every transition (admission, transfer, discharge) — critical to prevent recurrence

— Updated allergy/interaction list in EMR — flag combinations (e.g., "Do not co-prescribe linezolid with SSRI")

— Communication with outpatient pharmacy about avoided drugs

— Written discharge instructions in patient's preferred language and literacy level

— Polypharmacy disproportionately affects elderly, low-income, and patients with multiple providers — ensure single medication home when possible

Step 3 management: A patient on fluoxetine prescribed linezolid by another team who develops SS — your duty is immediate disclosure to family, root-cause analysis filing, and an EMR allergy entry. Do not minimize or attribute solely to the patient.

Board pearl: "Just culture" — focus on system failure (no interaction check) over individual blame.

Iatrogenic harm and disclosure:

Mandatory reporting and safety nets:

Informed consent in altered patients:

Transition-of-care safety:

Health equity considerations:

High-Yield Associations and Rapid-Fire Clinical Facts

— SSRI + linezolid (MAOI activity)

— SSRI + MAOI (phenelzine, tranylcypromine, selegiline)

— SSRI + methylene blue (intra-op)

— SSRI + tramadol (very common)

— SSRI + meperidine

— SSRI + dextromethorphan (OTC cough)

— SSRI + ondansetron or metoclopramide

— SSRI + triptans (rare but tested)

— SSRI + St. John's wort

— MDMA alone or with SSRI

— Fentanyl high-dose + SSRI (peri-op)

— Spontaneous clonus

— Inducible clonus + agitation/diaphoresis

— Ocular clonus + agitation/diaphoresis

— Tremor + hyperreflexia

— Hypertonia + temp >38°C + clonus

— Stop offending agent

— Benzodiazepines first line

— Cyproheptadine 12 mg PO/NG loading dose

— Active cooling >38.5°C

— Intubation + paralysis (vecuronium/rocuronium, NOT succinylcholine) >41°C

— Fluoxetine: 5 weeks before MAOI

— Other SSRIs: 2 weeks before MAOI

— MAOI: 2 weeks before any serotonergic drug

— SS: clonus, hyperkinetic, hours

— NMS: rigidity, hypokinetic, days

— MH: anesthesia trigger, masseter rigidity, dantrolene

— Anticholinergic: dry skin, no clonus

— "Started linezolid 2 days ago for cellulitis"

— "Recently added tramadol for back pain"

— "Took extra dose of cough syrup with dextromethorphan"

— "MDMA at a music festival last night"

Board pearl: Lower-extremity clonus > upper-extremity clonus — this asymmetry is a specific finding for serotonin syndrome.

Drug combinations that classically trigger SS:

Hunter criteria — must memorize:

Treatment essentials:

Washout periods:

Key distinctions:

Common Step 3 vignette markers:

Board Question Stem Patterns

— 45-year-old on sertraline started on linezolid for MRSA cellulitis. 12 hours later: tremor, diaphoresis, agitation, hyperreflexia, ankle clonus.

— Best next step: Discontinue linezolid AND sertraline, IV lorazepam, supportive care, cyproheptadine if not improving.

— 22-year-old at a rave, took MDMA, now presenting with hyperthermia (40.5°C), agitation, ocular clonus, mydriasis.

— Best next step: IV benzodiazepines, aggressive cooling, IV fluids; ICU admission.

— 16-year-old took multiple doses of dextromethorphan-containing cough syrup while on fluoxetine. Tremor, hyperreflexia, anxiety.

— Best diagnostic clue: Recent SSRI + DM ingestion = serotonin syndrome.

— Patient on chronic citalopram receives methylene blue during parathyroid surgery. Develops hyperthermia, rigidity, clonus post-op.

— Diagnosis: Serotonin syndrome from methylene blue (MAOI activity).

— Patient on haloperidol AND fluoxetine. Develops rigidity, fever, AMS over 5 days.

— Key distinguishing features: Slow onset, lead-pipe rigidity, no clonus → favor NMS.

— 3-year-old found with empty bottle of mom's sertraline. Now agitated, tremulous, tachycardic, with inducible clonus.

— Management: Stabilize, benzodiazepines, Poison Control, social work consult.

— Stable patient s/p mild SS asking when they can restart antidepressant.

— Answer: Restart single agent at lower dose 24–72 hours after full resolution; avoid the combination permanently.

— Patient with serotonin syndrome treated with succinylcholine for intubation — develops cardiac arrest from hyperkalemia (rhabdo).

— Lesson: Use non-depolarizing paralytic.

Step 3 management: When the stem mentions "started a new medication 24–48 hours ago" plus tremor/clonus/hyperreflexia, the answer is serotonin syndrome and discontinuation of the offending agent.

Pattern 1 — Drug-drug interaction:

Pattern 2 — Recreational drug use:

Pattern 3 — OTC misuse:

Pattern 4 — Peri-operative:

Pattern 5 — Differential with NMS:

Pattern 6 — Pediatric accidental ingestion:

Pattern 7 — Discharge planning:

Pattern 8 — Pharmacology pitfall:

One-Line Recap

Serotonin syndrome is a rapid-onset, life-threatening hyperserotonergic state diagnosed clinically by Hunter criteria (clonus, hyperreflexia, agitation, autonomic instability) in a patient on a serotonergic drug — managed by immediate discontinuation of the offending agent, benzodiazepines, active cooling, and cyproheptadine, with ICU-level care and paralysis for hyperthermia >41°C.

— Onset <24 hours after drug change/addition (vs days for NMS)

— Clonus (spontaneous, inducible, ocular) — the diagnostic anchor

— Hyperkinetic features: tremor, hyperreflexia, hyperactive bowel sounds, diaphoresis with moist skin

— Common triggers: SSRI + linezolid/MAOI/tramadol/dextromethorphan/methylene blue

— Stop all serotonergic agents immediately

— IV benzodiazepines first-line (lorazepam 1–2 mg IV titrated)

— Cyproheptadine 12 mg PO/NG loading dose for moderate-severe cases

— Active cooling if temp >38.5°C; intubate + paralyze with vecuronium/rocuronium if temp >41°C

— Avoid succinylcholine, dantrolene, bromocriptine, antipyretics, physical restraints alone, long-acting beta-blockers

— Mild → observation 6–24h, discharge with PCP follow-up 48–72h

— Moderate → telemetry admission with cyproheptadine

— Severe → ICU with cooling and paralysis

— Document interaction in EMR, disclose iatrogenic events, reconcile medications at every transition, counsel patient on OTC/herbal avoidance and bracelet, restart antidepressant only after full recovery with single agent at lower dose

Board pearl: If you remember one thing — clonus + serotonergic drug = serotonin syndrome; stop the drug, give benzos, cool the patient. That's 80% of the Step 3 points.

Recognition pearls:

Management essentials:

Disposition and follow-up: